Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside.
Immunological risk stratification has a central role in determining both the feasibility of solid organ transplantation and the type (and amount) of induction and maintenance immunosuppressive therapy. Currently there is poor consensus on how to exactly estimate the global immunological risk, and most transplant centers adopt complicated internal guidelines for risk stratification. Here we systematically review published evidences that should drive appropriateness in risk stratification, focusing on donor-specific antibodies against HLA and other antigens.
a Department of Translational Research , University of Pisa , Pisa , Italy.
Daniele
D
Focosi
D000818:Animals; D001788:Blood Grouping and Crossmatching / Q000379:methods*; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood*; D007519:Isoantigens / Q000276:immunology; D016377:Organ Transplantation; D012306:Risk; D014019:Tissue Donors
D006680:HLA Antigens; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D007519:Isoantigens
Anti-HLA antibodies; Luminex; crossmatch; donor-specific antibodies; risk stratification; transplantation